View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Orasure Technologies Inc: 4 directors

Four Directors at Orasure Technologies Inc bought 197,284 shares at between 3.060USD and 3.173USD. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OraSure Reports Fourth Quarter 2024 Financial Results

OraSure Reports Fourth Quarter 2024 Financial Results BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2024. “Our Q4 revenue was consistent with our expectations, including 10% growth in our core revenue. We continue to see signs of gradual recovery in our key end markets, and we are diversifying our business by expanding our product portfolio and adding new customers, offset by eleva...

 PRESS RELEASE

OraSure to Announce Fourth Quarter 2024 Financial Results and Host Ear...

OraSure to Announce Fourth Quarter 2024 Financial Results and Host Earnings Call on February 25th BETHLEHEM, Pa., Feb. 14, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2024 financial results and certain business developments for 5 p.m. ET on February 25, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The...

 PRESS RELEASE

OraSure to Present at the J.P Morgan Healthcare Conference

OraSure to Present at the J.P Morgan Healthcare Conference BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. OraSure’s presentation is scheduled for Thursday, January 16, 2025 at 9:00 a.m. PT. A live webcast and replay of the presentation will be available in the “Events and Presentations” section of OraSure’s investor relations website at ....

 PRESS RELEASE

CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescen...

CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th by OraSure Technologies, Inc. (NASDAQ: OSUR), please note that the first sentence of the release (read "OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents.") is incomplete. The corrected release follows:  OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that The...

 PRESS RELEASE

OraQuick® HIV Self-Test Now Approved for Use in Adolescents

OraQuick® HIV Self-Test Now Approved for Use in Adolescents BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older. According to the most recent data available from the Centers for Disease Control & Prevention, it is estimated that 19 percent of new HIV diagnoses in the United States were among young people aged 13 to 24, and ...

 PRESS RELEASE

OraSure Technologies Acquires Sherlock Biosciences

OraSure Technologies Acquires Sherlock Biosciences BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure’s innovation pipeline with the addition of Sherlock’s molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specif...

 PRESS RELEASE

OraSure Receives Federal Funding for Development of Marburg Virus Rapi...

OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and R...

 PRESS RELEASE

OraSure to Participate in Upcoming Investor Conference

OraSure to Participate in Upcoming Investor Conference BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment Conference on Wednesday, November 20, with a Q&A session scheduled for 1 p.m. ET A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at . The webcast will be archived on OraSure’s website and will be available for approximately 90 days. About OraSure Techn...

 PRESS RELEASE

OraSure Reports Q3 ’24 Revenue of $39.9 Million

OraSure Reports Q3 ’24 Revenue of $39.9 Million Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three mon...

 PRESS RELEASE

OraSure to Announce Third Quarter 2024 Financial Results and Host Earn...

OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webca...

 PRESS RELEASE

OraSure Technologies Elects Jack Kenny to the Board of Directors

OraSure Technologies Elects Jack Kenny to the Board of Directors BETHLEHEM, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the election of Jack Kenny to its Board of Directors, effective September 9, 2024. With the addition of Mr. Kenny, OraSure’s Board of Directors currently has seven members. Mr. Kenny is the former Chief Executive Officer for Meridian Bioscience, where he led the company’s turnaround before it was acquired. He has more than 30 years...

 PRESS RELEASE

OraSure Reports Q2 ’24 Revenue of $54.3 Million

OraSure Reports Q2 ’24 Revenue of $54.3 Million Q2 GAAP EPS of $(0.01); Q2 Non-GAAP EPS of $0.07 OraQuick® HCV Self-test is the first globally to earn WHO pre-qualification Strong momentum with Syphilis Health Check™ launch Expanding Sample Management applications into saliva-based liquid biopsy BETHLEHEM, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2024. “Our team continues to execute well...

 PRESS RELEASE

OraSure to Announce Second Quarter 2024 Financial Results and Host Ear...

OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th BETHLEHEM, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2024 financial results and certain business developments for 5 p.m. ET on August 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast...

 PRESS RELEASE

OraSure Technologies Supports National HIV Testing Day

OraSure Technologies Supports National HIV Testing Day BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced its support of HIV testing initiatives taking place across the nation in recognition of National HIV Testing Day, held each year on June 27th. These testing initiatives will help encourage thousands of people across the U.S. to get tested for HIV. According to the Centers for Disease Control & Prevention, it is estimated that 1.2 million people...

 PRESS RELEASE

OraSure Reports Q1 ’24 Revenue of $54.1 Million

OraSure Reports Q1 ’24 Revenue of $54.1 Million Q1 GAAP EPS of $(0.05); Q1 Non-GAAP EPS of $0.04 Restructuring initiatives expected to result in $15 million of annualized expense reductions once fully implemented and position OraSure to achieve cash flow breakeven for core business by end of 2024 Delivered initial orders for Syphilis Health Check™ as part of our distribution agreement with Diagnostics Direct BETHLEHEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, tod...

 PRESS RELEASE

OraSure to Announce First Quarter 2024 Financial Results and Host Earn...

OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch